DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/64d4e8/puerto_rico_pharma) has announced the addition of the "Puerto Rico Pharmaceuticals and Healthcare Report Q3 2011" report to their offering.
Puerto Rico Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Puerto Rico's pharmaceuticals and healthcare industry.
Puerto Rico's high per-capita healthcare and pharmaceutical spending represent a draw for manufacturers of patented drugs, which account for the majority of the territory's market. Many of those products are manufactured locally, given the advantages of lower costs in Puerto Rico than in mainland US. However, the island remains highly dependent on exports to the US, with changes in this market likely to have a major bearing on the development of Puerto Rico's pharmaceutical trade balance.
Additionally, underperforming economy and public sector spending cuts will conspire with upcoming patent expirations to keep annual growth rates of the Puerto Rico's pharmaceutical values at low levels.
Headline Expenditure Projections:
- Pharmaceuticals: US$2.75bn in 2010 to US$2.81bn in 2011; +2.0% in local currency terms. Forecast down slightly from Q211 due to macroeconomic factors.
- Healthcare: US$10.81bn in 2010 to US$11.06bn in 2011; +2.3% in local currency terms. Forecast down significantly from Q211 due to macroeconomic factors.
- Medical devices: US$528mn in 2010 to US$536mn in 2011; +1.7% in local currency terms. Forecast down slightly from Q211 due to macroeconomic factors.
Business Environment Rating: In our Q311 proprietary Business Environment Rating (BER) matrix for the Americas, Puerto Rico remains in an unchanged third position, after the US and Canada. Puerto Rico's composite score is also unchanged, at 65.6 out of a maximum 100. Its risks and rewards profiles are relatively evenly balanced, although concerns do exist over its economic structure and the extent of bureaucracy. However, in the long term, Puerto Rico will increasingly be challenged by Latin American countries, which are beginning to improve their business environments and increasingly offer the added bonus of massive domestic demand.
Key Topics Covered:
Executive Summary
SWOT Analysis
Pharmaceutical Business Environment Ratings
Puerto Rico - Market Summary
Regulatory Regime
Industry Developments
Industry Forecast Scenario
Competitive Landscape
Company Monitor
Country Snapshot: Puerto Rico Demographic Data
Glossary
Methodology
Companies Mentioned:
Pfizer
GlaxoSmithKline
Merck & Co
Abbott Laboratories
Novartis
Sanofi-Aventis
Eli Lilly
For more information visit http://www.researchandmarkets.com/research/64d4e8/puerto_rico_pharma